|
MRFAP1 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 9.45839999988429E-07 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
3.54399999999977E-05 |
| Normal-vs-Stage2 |
2.488400E-01 |
| Normal-vs-Stage3 |
2.4053999999607E-06 |
| Normal-vs-Stage4 |
2.20829999952876E-07 |
| Stage1-vs-Stage2 |
6.227500E-02 |
| Stage1-vs-Stage3 |
1.837830E-01 |
| Stage1-vs-Stage4 |
5.167800E-02 |
| Stage2-vs-Stage3 |
7.903300E-03 |
| Stage2-vs-Stage4 |
3.723700E-03 |
| Stage3-vs-Stage4 |
4.158400E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.78129999994781E-06 |
| Normal-vs-AfricanAmerican |
1.912490E-02 |
| Normal-vs-Asian |
3.363900E-03 |
| Caucasian-vs-AfricanAmerican |
4.277600E-01 |
| Caucasian-vs-Asian |
2.844200E-01 |
| AfricanAmerican-vs-Asian |
9.997800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
2.30109999999062E-06 |
| Normal-vs-Female |
4.02419999999681E-05 |
| Male-vs-Female |
3.780600E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
6.02709999999451E-05 |
| Normal-vs-Age(41-60Yrs) |
7.55080000000019E-05 |
| Normal-vs-Age(61-80Yrs) |
3.4172999996418E-07 |
| Normal-vs-Age(81-100Yrs) |
2.667600E-02 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
7.237000E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
2.104000E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
8.019200E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
1.138580E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
7.403400E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
8.229600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
6.39329999999605E-05 |
| Classical-VS-Follicular |
8.307800E-01 |
| Classical-VS-Other |
5.437400E-01 |
| Classical-VS-Normal |
1.020120E-04 |
| Tall-VS-Follicular |
1.938470E-03 |
| Tall-VS-Other |
4.055800E-01 |
| Tall-VS-Normal |
2.42919995230295E-09 |
| Follicular-VS-Other |
6.839800E-01 |
| Follicular-VS-Normal |
8.808100E-04 |
| Other-VS-Normal |
2.732200E-02 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.758110E-04 |
| Normal-vs-N1 |
5.59919999254532E-10 |
| N0-vs-N1 |
2.443400E-04 |
|
|
